Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 4/20 | 0.36 |
| ▸ | LAP3 | P28838 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958472 | 0.95 | BLM (0.44) | LMNABLMFDPSLAP3ALDH1A1 | |
| SCHEMBL3741705 | 0.88 | FDPS (0.52) | FDPSLAP3ACE2 | |
| SCHEMBL9547924 | 0.84 | FDPS (0.48) | FDPSLAP3ACE2 | |
| SCHEMBL3737096 | 0.84 | FDPS (0.48) | FDPSLAP3ACE2 | |
| SCHEMBL7950976 | 0.81 | KDM4C (0.41) | FDPSLAP3KDM4CKDM4APHF8 | |
| SCHEMBL7570633 | 0.81 | KDM4C (0.41) | FDPSLAP3KDM4CKDM4APHF8 | |
| SCHEMBL7947910 | 0.81 | KDM4C (0.41) | FDPSLAP3KDM4CKDM4APHF8 | |
| SCHEMBL2302042 | 0.81 | KDM4C (0.41) | FDPSLAP3KDM4CKDM4APHF8 | |
| SCHEMBL2304432 | 0.79 | KDM4C (0.39) | LMNABLMFDPSLAP3KDM4C | |
| SCHEMBL7948679 | 0.79 | FDPS (0.45) | LMNABLMFDPSLAP3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015238-A1 | BLOOD FLOW PROMOTERS FOR CAUDA EQUINA TISSUES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015238-A1 | BLOOD FLOW PROMOTERS FOR CAUDA EQUINA TISSUES | PTGFR, PTGIS, PTGIR | LMNA 1814/4885BLM 4806/4885FDPS 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.